News - November 3, 2020
In light of the upcoming Pharmaceutical Strategy and ongoing Evaluation of the Orphan Medicinal Products (OMP) Regulation, the European Expert Group on Orphan Drug Incentives has been established to discuss and bring forward innovative proposals to stimulate innovation and foster research into new orphan drugs… read more
News - October 30, 2020
Pharmaceutical small to mid-sized companies and start-ups constitute a laboratory of innovation and should be nurtured through a forward-looking European incentives ecosystem that encourages the development of cutting-edge technologies. The upcoming EU health policy initiatives, including the Pharmaceutical Strategy for Europe and the impact assessment… read more
News - October 28, 2020
Sickle cell disease is one of the most prevalent genetic diseases in Europe. A recent report, commissioned by our member company Global Blood Therapeutics, use the latest data from 5 EU countries to draw recommendations to improve the life expectancy of people living with this… read more
News - September 30, 2020
Earlier this Summer the European Commission published its Roadmap for the Pharmaceutical Strategy for Europe which paved the way for a consultation process to which EUCOPE has contributed and will continue engage in the next months. Our position paper accompanying the general consultation is available… read more
Press Releases - August 11, 2020
Brussels 11 August 2020 – EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the evaluation of EU legislation on Orphan Medicinal Products… read more
Press Releases - August 11, 2020
EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the study on the EU Regulation 141/2000 on Orphan Medicinal Products (OMPs) (here below)…. read more
Events & Meetings / News - July 8, 2020
In the past two decades, a combination of scientific breakthrough coupled with strong incentives systems brought about great progress for rare disease patients. The number of medicines approved in Europe to treat rare diseases since 2000 increased from 8 to 169. However, with 95% of… read more
News / Press Releases - July 7, 2020
On the verge of the publication of the EU industrial strategy in March, EUCOPE shared the expectations and ambitions of its membership for a coherent strategy that harness Europe’s untapped potential: small and medium biopharma. The mission letter from President von der Leyen to Commissioner Kyriakides… read more
News - June 25, 2020
EUCOPE invites you to an online discussion on the future of rare diseases innovation to the benefit of patients in Europe. Entitled ‘How can Europe remain at the forefront of innovation to the benefit of patients with rare diseases?’, the event will take place online… read more
News - June 16, 2020
The European Commission just opened the public consultation on its proposed pharmaceutical strategy for the EU. In the Commission’s words, the strategy intends to ‘address the current issues of access, availability and affordability of medicines, while still promoting sustainable innovation and support EU industry to… read more
